JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2004; 44:2125-2132, doi:10.1016/j.jacc.2004.08.052
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maron, B. J.
Right arrow Articles by Seidman, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maron, B. J.
Right arrow Articles by Seidman, C. E.

VIEWPOINT

Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy

Barry J. Maron, MD, FACC*,*, J.G. Seidman, PhD*,{dagger} and Christine E. Seidman, MD*,{dagger}

* Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
{dagger} Department of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Manuscript received July 17, 2003; revised manuscript received July 30, 2004, accepted August 27, 2004.

* Reprint requests and correspondence: Dr. Barry J. Maron, Minneapolis Heart Institute Foundation, 920 E. 28th Street, Suite 60, Minneapolis, Minnesota 55407 (Email: hcm.maron{at}mhif.org).

Screening families with hypertrophic cardiomyopathy (HCM) presents a common clinical problem to practicing cardiologists, internists, and pediatricians. The traditional recommended strategy for screening relatives in most HCM families calls for such evaluations with echocardiography (and electrocardiogram [ECG]) on a 12- to 18-month basis, usually beginning at about age 12 years. If such tests show no evidence of left ventricular hypertrophy, i.e., without one or more segments of abnormally increased wall thickness by the time full growth and maturation is achieved (at the age of about 18 to 21 years), it has been customary practice to conclude that HCM is probably absent and reassure family members accordingly that further echocardiographic testing is unnecessary. However, novel developments in the definition of the genetic causes of HCM have defined both substantial molecular diversity and heterogeneity of the disease expression including (in some relatives) incomplete phenotypic penetrance and delayed, late-onset left ventricular hypertrophy well into adulthood. These observations have unavoidably reshaped the customary practice of genetic counseling and established a new proposed paradigm for clinical family screening of HCM families. Therefore, in the absence of genetic testing, strong consideration should be given to extending diagnostic serial echocardiography past adolescence and into mid-life for those family members with a normal echocardiogram and ECG. Of note, recent developments in laboratory DNA-based diagnosis for HCM could potentially avoid the necessity for serial echocardiography in many such relatives.

Abbreviations and Acronyms
  DNA = deoxyribonucleic acid
  ECG = electrocardiogram/electrocardiographic
  HCM = hypertrophic cardiomyopathy
  LV = left ventricle/ventricular
  PRKAG2 = AMP-activated protein kinase




This article has been cited by other articles:


Home page
Eur Heart JHome page
I. Ostman-Smith, G. Wettrell, B. Keeton, D. Holmgren, U. Ergander, S. Gould, C. Bowker, and M. Verdicchio
Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy
Eur. Heart J., May 1, 2008; 29(9): 1160 - 1167.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. Pelliccia, F. M. Di Paolo, F. M. Quattrini, C. Basso, F. Culasso, G. Popoli, R. De Luca, A. Spataro, A. Biffi, G. Thiene, et al.
Outcomes in Athletes with Marked ECG Repolarization Abnormalities
N. Engl. J. Med., January 10, 2008; 358(2): 152 - 161.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. Kasikcioglu
Gray zone problem in athletes
Eur. Heart J., October 1, 2007; 28(19): 2415 - 2416.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Ashrafian and H. Watkins
Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications: Cardiomyopathies: Therapeutics Based on Molecular Phenotype
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1251 - 1264.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. F. Nagueh and J. J. Mahmarian
Noninvasive Cardiac Imaging in Patients With Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2410 - 2422.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Richard, E. Villard, P. Charron, and R. Isnard
The Genetic Bases of Cardiomyopathies
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A79 - A89.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
G. F. Cox, L. A. Sleeper, A. M. Lowe, J. A. Towbin, S. D. Colan, E. J. Orav, P. R. Lurie, J. E. Messere, J. D. Wilkinson, and S. E. Lipshultz
Factors Associated With Establishing a Causal Diagnosis for Children With Cardiomyopathy
Pediatrics, October 1, 2006; 118(4): 1519 - 1531.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Pelliccia, F. M. Di Paolo, D. Corrado, C. Buccolieri, F. M. Quattrini, C. Pisicchio, A. Spataro, A. Biffi, M. Granata, and B. J. Maron
Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes
Eur. Heart J., September 2, 2006; 27(18): 2196 - 2200.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C. Wren
Screening children with a family history of sudden cardiac death.
Heart, July 1, 2006; 92(7): 1001 - 1006.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Kubo, H. Kitaoka, M. Okawa, Y. Matsumura, N. Hitomi, N. Yamasaki, T. Furuno, J. Takata, M. Nishinaga, A. Kimura, et al.
Lifelong Left Ventricular Remodeling of Hypertrophic Cardiomyopathy Caused by a Founder Frameshift Deletion Mutation in the Cardiac Myosin-Binding Protein C Gene Among Japanese
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1737 - 1743.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
B J Maron
Distinguishing hypertrophic cardiomyopathy from athlete's heart: a clinical problem of increasing magnitude and significance
Heart, November 1, 2005; 91(11): 1380 - 1382.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. C.P. Roos, T. M. Cox, M. Arad, B. J. Maron, and J.G. Seidman
Glycogen Storage Diseases and Cardiomyopathy
N. Engl. J. Med., June 16, 2005; 352(24): 2553 - 2553.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. J. Maron, P. S. Douglas, T. P. Graham, R. A. Nishimura, and P. D. Thompson
Task Force 1: Preparticipation screening and diagnosis of cardiovascular disease in athletes
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1322 - 1326.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.